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Ritonavir is the most potent and efficacious inhibitor of cytochrome P4503A (CYP3A), and it is used
accordingly for the pharmacoenhancement of other antiretrovirals. Paradoxically, ritonavir induces the clin-
ical metabolism and clearance of many drugs. The mechanism by which ritonavir inhibits and induces clinical
drug metabolism is unknown. Ritonavir induces CYP2B6 in human hepatocytes. This investigation tested the
hypothesis that ritonavir induces human CYP2B6 in vivo. Thirteen healthy human immunodeficiency virus-
negative volunteers underwent a three-way sequential crossover protocol, receiving racemic bupropion after
nothing (control), 3 days of treatment with ritonavir, and 2.5 weeks of treatment with ritonavir (400 mg twice
a day). Stereoselective bupropion hydroxylation was used as an in vivo probe for CYP2B6 activity. Plasma and
urine (R)- and (S)-bupropion and (R,R)- and (S,S)-hydroxybupropion concentrations were measured by liquid
chromatography-mass spectrometry. Racemic, (R)-, and (S)-bupropion plasma ratios of the area under the
concentration-time curve from 0 h to infinity (AUC0-) (ritonavir/control) were significantly reduced to 0.84,
0.86, and 0.80, respectively, after 3 days of ritonavir treatment and to 0.67, 0.69, and 0.60 after steady-state
ritonavir treatment. Apparent oral clearances for racemic, (R)-, and (S)-bupropion all were significantly
increased by 1.2-fold after 3 days of ritonavir treatment and by 1.4-, 1.7-, and 1.5-fold after steady-state
ritonavir treatment. The plasma (S,S)-hydroxybupropion/(S)-bupropion AUC0-72 ratio was significantly in-
creased by ritonavir. Formation clearances of both (R,R)- and (S,S)-hydroxybupropion were increased 1.8-fold
after 3 days of ritonavir treatment and 2.1-fold after steady-state ritonavir treatment. These results show that
ritonavir induces human CYP2B6 activity. Induction is rapid, occurring after only 3 days of ritonavir, and is
sustained for at least 2 weeks. The ritonavir induction of CYP2B6 activity may have significant implications for
drug interactions and clarify previously unexplained interactions.
Human immunodeficiency virus (HIV) drugs are notorious
perpetrators of drug interactions. The protease inhibitors
ritonavir, indinavir, nelfinavir, saquinavir, lopinavir, and am-
prenavir and the reverse transcriptase inhibitor efavirenz can
induce and/or inhibit the metabolism and clearance of numer-
ous drugs (45). Ritonavir is the most potent and efficacious
inhibitor of cytochrome P4503A (CYP3A), for which it is both
a substrate and a mechanism-based inhibitor (13). Ritonavir is
a standard component of highly active retroviral therapy and is
included for the pharmacoenhancement of other antiretrovi-
rals (boosting), which is achieved via greater bioavailability and
increased and sustained plasma concentrations. Boosting oc-
curs as a result of the inhibition of first-pass and hepatic
CYP3A activity and/or the inhibition of P-glycoprotein activity
(42).
Although traditionally associated with cytochrome P450
(CYP) inhibition, there is growing evidence that protease in-
hibitors also can cause CYP induction and attendant drug
interactions. Specifically, ritonavir has been shown to induce
CYP2B6 mRNA, protein expression, and catalytic activity in
human hepatocytes in vitro (8, 15). Clinically, ritonavir has been
shown to increase the metabolism and/or clearance of drugs such
as meperidine, ethinyl estradiol, olanzapine, trimethoprim-sulfameth-
oxazole, and methadone (45). Such induction might be at-
tributable to effects on CYP2B6 activity, since this isoform has
been shown to metabolize meperidine (44) and methadone
(20, 31, 47, 48). Nevertheless, the clinical effects of ritonavir on
human CYP2B6 activity are unknown.
The increasing significance of CYP2B6 in human drug me-
tabolism and disposition has been recognized recently, after
initially being considered a minor isoform of relative unimpor-
tance (12, 26, 49, 54). CYP2B6 catalyzes the bioactivation of
the antineoplastic agents ifosphamide, cyclophosphamide, and
tamoxifen, the metabolic inactivation of anesthetics and anal-
gesics such as methadone, meperidine, propofol, and keta-
mine, the biotransformation of abused drugs such as nicotine,
ecstasy, and phencyclidine, and pesticides and other environ-
mental contaminants. Notably, CYP2B6 also catalyzes the me-
tabolism of the antiretrovirals efavirenz and nevirapine (7, 46,
49). The proportion of drugs metabolized by CYP2B6 has been
estimated to be as high as 8% (39).
If ritonavir is a CYP2B6 inducer, this could explain the
increased elimination of several drugs. The purpose of this
investigation was to test the hypothesis that ritonavir is an
inducer of hepatic CYP2B6 activity in humans. Subjects were
studied after both acute and steady-state ritonavir treatment,
since there is some evidence that the duration of administra-
tion influences enzyme inhibition (short-term ritonavir) and
induction (long-term ritonavir) (22); there is clear evidence
that the induction of methadone clearance by ritonavir is rapid
(30, 34).
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The hydroxylation of (S)-bupropion was used as the in vivo
probe for CYP2B6 activity, since this has been shown to be an
improved CYP2B6 probe compared to racemic bupropion
(32). Although racemic bupropion clearance or hydroxylation
has been used clinically to phenotype CYP2B6 activity (35, 36,
41, 50), racemic bupropion suffers from well-documented lim-
itations. Specifically, bupropion clearance may not reflect al-
tered CYP2B6 activity, because hydroxylation is a minor met-
abolic pathway and there are alternate non-CYP2B6 routes of
bupropion metabolism; also, plasma hydroxybupropion con-
centrations are elimination rate limited (the metabolite half-
life exceeds that of the parent) rather than formation rate
limited (36, 50). Both (R)- and (S)-bupropion were hydroxy-
lated by CYP2B6, but the metabolism was stereoselective (4),
and clinically, the apparent oral clearance (CL/F) of (S)-bu-
propion was threefold greater than that of (R)- and (R,S)-
bupropion (32). More importantly, (S,S)-hydroxybupropion
was formation rate limited, while (R,R)-hydroxybupropion and
(R,R),(S,S)-hydroxybupropion were elimination rate limited;
hence, (S,S)-hydroxybupropion formation is a better in vivo
CYP2B6 probe (32).
MATERIALS AND METHODS
Study population and protocol. Thirteen volunteers (four males, nine females)
participated in the investigation, which was approved by the Washington Uni-
versity Institutional Review Board, after written informed consent was obtained.
Inclusion criteria included being (i) 18 to 40 years old and (ii) within 30% of ideal
body weight. Exclusion criteria were (i) major medical problems; (ii) a history of
liver or renal disease; (iii) the use of prescription medications, drugs, herbals, and
foods metabolized by or altering CYP2B6 or CYP3A4; and (iv) a family history
of type 2 diabetes. Females taking hormonal contraceptives were excluded from
enrollment. Both smokers and nonsmokers were enrolled. Subjects underwent a
screening visit, during which blood samples for fasting glucose concentration and
HIV serologic status were obtained. Subjects were excluded if their glucose
exceeded 110 mg/dl (because ritonavir can cause glucose intolerance) or if they
were HIV seropositive (since monotherapy can cause HIV resistance). The final
study population was comprised of 13 subjects (29  5 years [range, 23 to 39
years], 67  9 kg [range, 53 to 84 kg]). One additional subject completed the
control session but withdrew after starting ritonavir due to nausea, fatigue, and
cramping, and the control session data are not included in the data set.
The protocol used a three-session sequential crossover design (with the control
session first due to logistical considerations). There was at least a 2-week washout
between the first two study sessions. Subjects were instructed to consume no
orange-, apple-, or grapefruit-containing foods or juices for 5 days before and on
each study day and no alcohol or caffeine for 24 h before and on each study day.
An intravenous catheter was placed in an arm vein for blood sampling. Subjects
received 150 mg oral immediate-release bupropion on three occasions after no
pretreatment (control), on the 3rd day of ritonavir treatment, and on the 17th
day of ritonavir treatment. Ritonavir dosing was 200 mg three times daily for 1
day, 300 mg twice daily for the next 6 days, and then 400 mg twice daily. The last
ritonavir dose was taken the night before the last blood sample, and the total
duration of administration was 18 days. Previous investigations suggested that
steady-state induction is achieved after approximately 2 weeks of ritonavir (28,
40, 43). Venous blood samples were obtained for 48 h after bupropion treatment,
and plasma was separated and stored at 20°C for later analysis. All urine was
collected for 48 h after bupropion treatment as two 24-h collections, the volume
was measured, and an aliquot was stored at 20°C for later analysis. Subjects
were fed a light breakfast 3 h after bupropion administration and had free access
to food and water thereafter.
Analytical methods. Plasma and urine (R)- and (S)-bupropion and (R,R)- and
(S,S)-hydroxybupropion concentrations were measured by high-performance liq-
uid chromatography-tandem mass spectrometry as described previously (3). In-
terday coefficients of variation were the following: for 1, 10, and 100 ng/ml
(R)-bupropion, 9, 9, and 8%, respectively; for 1, 10, and 100 ng/ml (S)-bupropion,
10, 9, and 10%, respectively; for 5, 50, and 500 ng/ml (R,R)-hydroxybupropion,
10, 5, and 8%, respectively; and for 5, 50, and 500 ng/ml (S,S)-hydroxybupropion,
8, 6, and 3%, respectively.
Pharmacokinetic analysis. Data were analyzed using noncompartmental
methods (WinNonlin 5.1; Pharsight Corp., Mountain View, CA) as described
previously (33). The CL/F was the ratio of the dose to the area under the
concentration-time curve (AUC), and the apparent renal or formation clear-
ance was calculated as the product of the fraction of the dose recovered in
urine and CL/F.
Sample size. For statistical power calculations, we consider a simplified anal-
ysis (paired t test) for comparing control and HIV drug treatments that was
based on the primary outcome variable: the plasma hydroxybupropion/bupro-
pion AUC ratio. Intraindividual variability in this parameter has not been de-
termined; hence, it could not be used for sample size calculation. Nevertheless,
experience with within-subject (interday) variability in the clearance of other
P450 probes suggested that the intraindividual coefficients of variation typically
were 30 to 40%. For a primary outcome variable, detecting a 30% change
(standard deviation [SD], 35%; , 0.05; , 0.8) would require 13 subjects. Fur-
thermore, previous induction studies using 12 subjects were adequately powered
to detect induction (30).
Statistical analysis. Results are expressed as the means  SD or median.
Analysis of variance was used to assess the significance of differences between
treatments (SigmaStat 3.5; Systat Corp). Nonnormal data were log transformed
for statistical analysis. Significance was assigned at P 0.05. Differences between
treatments in clearances and AUC ratios also were assessed as the geometric
mean ratios (ritonavir/control) and the 90% confidence intervals of the geomet-
ric means. Confidence intervals excluding unity were considered statistically
significant.
RESULTS
One subject withdrew (for scheduling reasons) during the
steady-state ritonavir phase of the protocol; thus, data were not
obtained for this subject session. Results are presented for 13
subjects (control and 3 days of ritonavir) and for 12 subjects
(2.5 weeks of ritonavir).
Ritonavir caused significant changes in bupropion disposi-
tion. Plasma concentrations of both (R)- and (S)-bupropion
were diminished after both 3 days of ritonavir treatment and
steady-state ritonavir treatment (Fig. 1). The ratios of plasma
AUC from 0 h to infinity (AUC0-) (ritonavir/control) for
racemic, (R)-, and (S)-bupropion were significantly reduced to
0.84, 0.86, and 0.80, respectively, after 3 days of ritonavir treat-
ment and to 0.67, 0.69, and 0.60 after more than 2 weeks of
ritonavir treatment (Table 1). (R)-, (S)-, and racemic bupro-
pion CL/Fs all were significantly increased by 1.2-fold after 3
days of ritonavir treatment and by 1.4-, 1.7, and 1.5-fold after
steady-state ritonavir treatment. Short-term ritonavir de-
creased the plasma AUC0- of total and (R,R)-hydroxybupro-
pion but not (S,S)-hydroxybupropion, while steady-state
ritonavir treatment decreased the plasma AUC0- of total,
(R,R)-, and (S,S)-hydroxybupropion (Fig. 2). The median ap-
parent elimination half-life of total, (R,R)-, and (S,S)-hydroxy-
bupropion was reduced from 32, 33, and 18 h, respectively, to
17, 18, and 13 h by 3 days of ritonavir treatment and to 11 h for
all three by steady-state ritonavir treatment. The plasma hy-
droxybupropion/bupropion AUC0-48 ratios for racemic and
(R)-bupropion were minimally changed or were unchanged by
both short-term and steady-state ritonavir treatments, while
the metabolite/parent ratio for (S)-bupropion was increased by
both short-term and steady-state ritonavir treatments. Ritona-
vir caused a 1.8-fold increase in the formation clearance of
both (R,R)- and (S,S)-hydroxybupropion after 3 days and a
2.1-fold increase after 2 weeks (Table 2). Similar results were
observed for the 0- to 24-h urine hydroxybupropion/bupropion
molar ratio. Ritonavir had no effect on bupropion enantiomer
renal clearance.
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This investigation demonstrates that short-term (3 days) and
steady-state ritonavir treatments significantly increased (S)-
bupropion hydroxylation. Specifically, ritonavir increased
(S,S)-hydroxybupropion apparent formation clearance, 0- to
24-h urine (S,S)-hydroxybupropion/(S)-bupropion molar ra-
tios, plasma (S,S)-hydroxybupropion/(S)-bupropion AUC ra-
tios, and (S)-bupropion CL/F. Changes in (S)-bupropion clear-
ance were not due to increased bupropion renal clearance.
(S)-Bupropion hydroxylation is catalyzed selectively by
CYP2B6 and an in vivo probe for CYP2B6 (32). Therefore,
these results strongly support the conclusion that human he-
patic CYP2B6 activity in vivo is induced by both short-term
and steady-state ritonavir treatments, with the latter causing an
approximately twofold increase. Although ritonavir also in-
creased apparent formation clearances, urine hydroxybupro-
pion/bupropion molar ratios, and systemic clearance of (R,R)-
and racemic hydroxybupropion, plasma hydroxybupropion/
bupropion AUC ratios were decreased rather than increased.
There is insufficient understanding of hydroxybupropion elim-
ination to explain this last observation (32).
One previous investigation evaluated the effects of ritonavir
on bupropion disposition (24). Subjects received bupropion
(presumably the immediate-release variety, although it was not
specified) on the second day of treatment with 200 mg ritonavir
twice daily. Racemic bupropion and metabolite plasma con-
centrations were measured for 24 h. Neither bupropion nor
hydroxybupropion concentrations were significantly altered by
ritonavir, and the hydroxybupropion/bupropion ratio was in-
significantly decreased by 15%, which was interpreted as sug-
gesting no effect on CYP2B6 activity. There are, however,
differences between previous studies and the present study.
Hesse et al. evaluated racemic bupropion plasma concentra-
tions and the hydroxybupropion/bupropion AUC ratio (24).
Nevertheless, plasma bupropion concentrations may be insen-
sitive to altered CYP2B6 activity, because CYP2B6-catalyzed
hydroxylation is only a minor route of overall bupropion elim-
ination (36, 50). Additionally, the plasma hydroxybupropion/
bupropion AUC ratio may be confounded, because racemic
hydroxybupropion is elimination rate rather than formation
rate limited, and hydroxybupropion elimination also may be
altered (32, 36). Hesse et al. also evaluated bupropion metab-
olism after fewer and lower doses of ritonavir (three to four
doses of 200 mg) than those used herein (3 days of two doses
of 200 mg and three to four doses of 300 mg and 2.5 weeks of
400 mg twice daily) and speculated that longer ritonavir expo-
sure might induce CYP2B6. The present investigation demon-
strates that both short-term and steady-state ritonavir treat-
ments do induce hepatic CYP2B6 activity.
The ritonavir induction of hepatic CYP2B6 is consistent
with previous in vitro findings. Ritonavir increased CYP2B6
mRNA expression in LS180 adenocarcinoma cells (23) and
induced CYP2B6 mRNA expression, immunoreactive protein
expression, and catalytic activity in primary human hepatocytes
(8, 15). Ritonavir was classified as a strong in vitro CYP2B6
inducer, along with rifampin, phenobarbital, phenytoin, and
clotrimazole (15).
Other CYP2B6 inducers also have been shown to induce the
metabolism of racemic bupropion and other CYP2B6 sub-
strates. The prototypic CYP2B6 inducer rifampin induced bu-
propion clearance by threefold and increased peak plasma
hydroxybupropion concentrations (36). Lopinavir/ritonavir
(400 mg lopinavir/100 mg ritonavir twice daily for 2 weeks)
decreased the plasma AUC for bupropion and hydroxybupro-
pion by 57 and 50%, respectively (27). Ritonavir (500 mg twice
daily for 10 days) decreased the plasma meperidine AUC and
increased the normeperidine AUC, suggesting the induction of
metabolism (43). Although this was initially attributed to
CYP3A induction (43), subsequent reports showing that me-
peridine is primarily a CYP2B6 substrate (44) and that ritona-
vir does not induce CYP3A4 (see below) suggest that the
ritonavir enhancement of meperidine metabolism and clear-
ance likely reflects CYP2B6 induction.
The ritonavir induction of hepatic CYP2B6 activity has clin-
FIG. 1. Plasma concentrations of racemic bupropion (A) and bupropion enantiomers (B and C). Results are the means  SD (n  13 for
controls and acute ritonavir treatment; n  12 for steady-state ritonavir treatment). Some SD are omitted for clarity.
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ical implications, specifically with regard to the disposition of
numerous CYP2B6 substrates, including antineoplastic agents,
anesthetics and analgesics, drugs of abuse, antiretrovirals, pes-
ticides, and other environmental contaminants, together en-
compassing as much as 8% of all therapeutic drugs (39, 49, 54).
One example is the ritonavir induction of nelfinavir metabo-
lism, evidenced by increased plasma ratios of metabolite M8/
nelfinavir (1). Another notable example is methadone, a main-
stay in the treatment of opiate addiction and acute and chronic
pain. Ritonavir increases methadone clearance and can cause
acute withdrawal (19, 30, 34, 38). Both short-term and steady-
state ritonavir treatments recently were shown to increase in-
travenous and oral methadone metabolism and clearance by
1.5- to 2-fold (30, 34). This occurred despite the profound
ritonavir inhibition of CYP3A. The mechanism by which
ritonavir induces methadone clearance is unknown. Metha-
done metabolism and clearance in vivo traditionally have been
attributed to CYP3A (5, 10, 18) and ritonavir effects on meth-
adone disposition to CYP3A induction (19, 38). Notwithstand-
ing years of the clinical use of these drugs, the paradox of the
ritonavir induction of methadone clearance despite CYP3A
inhibition remains unexplained. Recent evidence suggests a
TABLE 1. Pharmacokinetic parameters for plasma bupropion and hydroxybupropiona
Substance and parameterb
Results according to treatment typec
Control
(n  13) Acute ritonavir (n  13) Steady-state ritonavir (n  12)
Mean  SD Mean  SD Ratio Mean  SD Ratio
Bupropion
Cmax (ng/ml) 312  142 345  245 267 143
AUC0- (h  ng  ml
1) 1,440  520 1,290  700 0.84 (0.72, 0.97) 1,030  660* 0.67 (0.53, 0.83)
CL/F (liter  min1) 1.93  0.61 2.47  1.24 1.19 (1.03, 1.38) 3.24  1.52* 1.50 (1.21, 1.87)
Elimination t1/2 (h) 18.7  6.6 16.8  5.8 17.8 6.4
(R)-Bupropion
Cmax (ng/ml) 203  100 235  186 188 114
AUC0- (ng  h  ml
1) 927  386 866  553 0.86 (0.74, 0.99) 713  517 0.69 (0.56, 0.86)
CL/F (liter  min1) 1.54  0.54 1.96  1.07* 1.17 (1.01, 1.35) 2.51  1.30* 1.44 (1.16, 1.78)
Elimination t1/2 (h) 17.6  5.6 15.9  5.5 17.3 5.7
(S)-Bupropion
Cmax (ng/ml) 109  45 110  61 80 35
AUC0- (h  ng  ml
1) 509  148 423  167* 0.80 (0.69, 0.93) 318  166* 0.60 (0.46, 0.76)
CL/F (liter  min1) 2.65  0.77 3.45  1.46* 1.25 (1.08, 1.45) 4.96  2.32* 1.68 (1.31, 2.15)
Elimination t1/2 (h) 19.4  8.1 17.6  6.4 18.4 7.6
Hydroxybupropion
Cmax (ng/ml) 335  148 345  192 330 191
Tmax (h) 3.7  1.7 3.6  2.3 3.4 2.3
AUC0-72 (h  ng  ml
1) 9,640  4,650 8,470 4,200 0.86 (0.80, 0.93) 6,100 2,870 0.62 (0.51, 0.75)
AUC0- (h  ng  ml
1) 15,490  8,530 11,330 6,050 0.69 (0.59, 0.89) 7,560 4,130 0.43 (0.31, 0.70)
Elimination t1/2 (hr) 31.9  8.1 22.6  14.2 18.6 17.4*
AUC0-72 hydroxybupropion/bupropion (h  ng  ml
1) 8.4  5.2 9.0  7.4 1.02 (0.90, 1.15) 8.4  6.0 0.92 (0.79, 1.07)
AUC0- hydroxybupropion/bupropion (h  ng  ml
1) 12.0  8.3 10.6  8.4 0.89 (0.76, 1.06) 9.1  5.8 0.73 (0.58, 0.97)
(R,R)-Hydroxybupropion
Cmax (ng/ml) 317  139 325  184 311 182
Tmax (h) 3.8  1.7 3.8  2.2 3.5 2.2
AUC0-72 (h  ng  ml
1) 9,290  4,510 8,120 4,080* 0.86 (0.79, 0.93) 5,829 2,790* 0.61 (0.50, 0.74)
AUC0- (h  ng  ml
1) 15,240  8,450 10,950 5,930* 0.68 (0.58, 0.89) 7,330 4,140* 0.42 (0.30, 0.71)
Elimination t1/2 (hr) 33.1  9.1 23.1  15.1* 19.3 19.1*
AUC0-72 hydroxybupropion/bupropion (h  ng  ml
1) 12.7  8.0 13.4  11.5 0.99 (0.86, 1.13) 12.2  9.0 0.87 (0.75, 1.01)
AUC0- hydroxybupropion/bupropion (h  ng  ml
1) 18.8  13.5 16.1  13.2 0.86 (0.72, 1.03) 13.4  8.8 0.68 (0.52, 0.94)
(S,S)-Hydroxybupropion
Cmax (ng/ml) 20  11 25  14 23 13
Tmax (h) 2.2  1.5 1.7 .0.8 1.5  0.6
AUC0-72 (h  ng  ml
1) 352  206 356  165 1.04 (0.95, 1.14) 274  117 0.81 (0.67, 0.97)
AUC0- (h  ng  ml
1) 420  251 404  180 0.99 (0.90, 1.10) 303  123 0.75 (0.61, 0.92)
Elimination t1/2 (h) 18.1  2.8 15.3  6.1 13.9 7.3
AUC0-72 hydroxybupropion/bupropion (h  ng  ml
1) 0.84  0.56 1.05  0.69* 1.28 (1.11, 1.47) 1.15  0.67* 1.33 (1.07, 1.66)
AUC0- hydroxybupropion/bupropion (h  ng  ml
1) 0.89  0.60 1.06  0.66* 1.24 (1.11, 1.39) 1.13  0.62* 1.26 (1.02, 1.55)
a Subjects received 150 mg oral immediate-release racemic bupropion alone on the 3rd day of ritonavir (300 mg twice daily) treatment or on the 17th day of ritonavir
(400 mg twice daily) treatment.
b Cmax, maximum concentration of drug in plasma; Tmax, time to maximum concentration of drug in plasma; t1/2, elimination half-life.
c Parameter ratios (ritonavir/control) are the geometric means and the 90% confidence intervals about the geometric means (in parentheses). An asterisk indicates
a value that is different from that for the control (P  0.05).
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significant, if not predominant, role for CYP2B6 in methadone
metabolism and clearance (20, 31, 47, 48). CYP3A inhibition
failed to diminish methadone metabolism and clearance (30,
31, 34). Conversely, rifampin, which induces CYP2B6, in-
creased methadone metabolism and clearance at a level similar
to that by ritonavir. This suggests that the ritonavir induction
of methadone metabolism and clearance may be mediated by
hepatic CYP2B6 induction.
The clinical effects of ritonavir on human hepatic CYP2B6
are diametrically opposite to those on hepatic and intestinal
CYP3A. Ritonavir is one of the most potent and efficacious
mechanism-based inhibitors of CYP3A isoforms in vitro (13).
Clinically, acute and steady-state ritonavir treatments pro-
foundly inhibit first-pass and hepatic CYP3A. Several recent
investigations, using well-characterized CYP3A probes such as
midazolam, triazolam, and alfentanil, demonstrated 	95% in-
hibition of first-pass CYP3A activity by various ritonavir regi-
mens, such as 100 to 200 mg/day, 200 mg twice daily, and 400
mg twice daily (6, 17, 22, 30, 34). Although early clinical in-
vestigations suggested that steady-state ritonavir treatment in-
duced CYP3A based on the autoinduction of ritonavir clear-
ance (29) and decreased ethinyl estradiol AUC and half-life
(40), nevertheless it was recognized that such effects also could
emanate from ritonavir induction of efflux transporters (6).
FIG. 2. Plasma concentrations of racemic hydroxybupropion (A) and hydroxybupropion diastereomers (B and C). Results are the means  SD
(n  13 for controls and acute ritonavir treatment; n  12 for steady-state ritonavir treatment). Some SDs are omitted for clarity.
TABLE 2. Pharmacokinetic parameters for urine bupropion and hydroxybupropion
Parameter and substance
Results according to treatment typea
Control
(n  13) Acute ritonavir (n  13) Steady-state ritonavir (n  12)
Mean  SD Mean  SD Ratio Mean  SD Ratio
Apparent renal or formation clearance
(ml/min)b
Racemic bupropion 16  18 20 18 1.09 (0.76, 1.58) 21  28 1.11 (0.69, 1.79)
(R)-Bupropion 21 23 25 23 1.10 (0.75, 1.60) 28 42 1.09 (0.67, 1.78)
(S)-Bupropion 9 10 10 8 1.02 (0.71, 1.47) 10  10 1.14 (0.74, 1.76)
Hydroxybupropion 63 44 143 168* 1.78 (1.34, 2.36) 183 179* 2.09 (1.46, 2.98)
(R,R)-Hydroxybupropion 72 51 172 215* 1.78 (1.30, 2.42) 217 221* 2.07 (1.43, 2.99)
(S,S)-Hydroxybupropion 49 35 96 88* 1.75 (1.38, 2.21) 134 133* 2.12 (1.47, 3.06)
Hydroxybupropion/bupropion molar ratio
at 0–24 hc
Hydroxybupropion/bupropion 4.5 3.7 8.5 6.8* 1.76 (1.10, 2.81) 15.4 20.4* 2.04 (1.10, 3.77)
(R,R)-Hydroxybupropion/(R)-
bupropion
4.1  3.4 7.7 6.2* 1.76 (1.08, 2.87) 14.7  20.0* 2.10 (1.10, 4.00)
(S,S)-Hydroxybupropion/(S)-bupropion 6.0 4.7 11.7 8.5* 1.83 (1.20, 2.80) 18.6 22.9* 1.95 (1.15, 3.31)
a Subjects received 150 mg oral immediate-release racemic bupropion alone on the 3rd day of ritonavir (300 mg twice daily) treatment or on the 17th day of ritonavir
(400 mg mg twice daily) treatment. Parameter ratios (ritonavir/control) are the geometric means and the 90% confidence intervals about the geometric means (in
parentheses). An asterisk indicates that the value is significantly different from that for the control (P  0.05).
b Based on 0 to 48 h of urine collection.
c Based on 0 to 24 h of urine collection.
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The contradictory effects of ritonavir on human hepatic
CYP2B6 and CYP3A activities are paradoxical, particularly
since these isoforms share common regulatory pathways. The
orphan nuclear receptors pregnane X receptor (PXR) and
constitutive androstane receptor (CAR) both regulate the ex-
pression of CYP2B and CYP3A (51). Early investigations sug-
gested that PXR and CAR were the predominant activators of
CYP3A and CYP2B, respectively, although later findings of
cross-talk between PXR and CAR demonstrated the recipro-
cal activation of their response elements (52). Cross-talk is
asymmetrical, so that the activation of human PXR, which has
a large and accommodating active site that binds numerous
and diverse ligands (2, 11), results in the nonselective activa-
tion of both CYP2B6 and CYP3A4 (14). Conversely, human
CAR, which has a smaller binding site (53), preferentially
activates CYP2B6 over CYP3A4 (14). A recent screen of
CYP2B6 and/or CYP3A4 inducers identified three classes: se-
lective human PXR activators (i.e., rifampin), mixed human
PXR and CAR activators (i.e., troglitazone), and preferential
human CAR activators (i.e., efavirenz and nevirapine) (16).
One possible explanation for reciprocal CYP2B6 induction/
CYP3A inhibition by ritonavir is PXR activation combined
with mechanism-based CYP3A inhibition. In human hepato-
cytes, ritonavir strongly activated PXR, upregulated CYP2B6
and CYP3A mRNA levels, and induced both CYP3A and
CYP2B6 protein expression (8, 9, 15, 23, 37). Ritonavir was the
most potent and efficacious PXR activator (15, 23), although it
was not as efficacious in inducing CYP3A4 as predicted by
PXR activation (23, 37). More importantly, while ritonavir
induced both CYP2B6 and CYP3A4 protein expression,
CYP3A activity was completely inhibited (8, 15, 37). Thus, the
PXR-mediated coordinate upregulation of CYP2B6 and
CYP3A4 expression by ritonavir was offset by the selective
inhibition of CYP3A4 and not CYP2B6. Ritonavir is a potent
(Ki 0.1 
M) mechanism-based CYP3A4 inhibitor (13, 21). It
appears to be a less potent inhibitor of CYP2B6 (50% inhib-
itory concentration, 2 
M) (25). A similar in vivo scenario
could result in the upregulation of both CYP3A4 and CYP2B6
expression, with the selective inhibition of CYP3A4 activity.
Another possible explanation for the reciprocal clinical ritona-
vir induction of CYP2B6 and inhibition of CYP3A is that
ritonavir is a preferential human CAR activator, resulting in
selective CYP2B6 upregulation and likely also CYP3A4 inhi-
bition. The antiretrovirals efavirenz and nevirapine have been
characterized as preferential human CAR activators (16); how-
ever, the effects of ritonavir on CAR have not been reported.
One potential limitation of this investigation is that the
steady-state ritonavir dose differs from that used in typical
contemporary antiretroviral regimens (42). In early clinical
use, ritonavir was dosed at 600 mg twice daily, although this
dose was associated with considerable drug interactions and
generally is no longer used for treating HIV-infected patients.
Contemporary use is predominately in lower doses, typically
100 to 200 mg once or twice daily. The present protocol was
designed as a mechanistic investigation specifically to provide
insights into the mechanism of the ritonavir induction of meth-
adone clearance in our previous investigation using the same
dose of 400 mg twice daily (30, 34). Nonetheless, CYP2B6
induction occurred at higher (400 mg twice daily) as well as
lower doses (after only 2 days of 200 to 300 mg twice daily) and
also after longer periods at 100 mg twice daily (27). Thus, the
present investigation has both mechanistic and clinical rele-
vance to ritonavir use at lower doses.
Ritonavir prescribing guidelines suggest that concomitant
use with bupropion increases, or is predicted to increase, bu-
propion concentrations. Caution is advised if bupropion is ad-
ministered with ritonavir, with a dosage reduction potentially
being necessary (Norvir [ritonavir] soft gelatin capsules and
oral solution prescribing information, Abbott Laboratories,
North Chicago, IL). This may be based in part on extrapolation
from the in vitro ritonavir inhibition of human liver micro-
somal bupropion hydroxylation (25). The present study dem-
onstrates the need for caution in extrapolating in vitro obser-
vations and the necessity of performing clinical investigations
to verify such observations, and it suggests that a revision of the
ritonavir dosing guidelines is appropriate.
In summary, the present investigation shows that short-term
(2 to 3 days) and steady-state ritonavir treatments increase the
hydroxylation and clearance of the CYP2B6 probe (S)-bupro-
pion, suggesting that ritonavir induces human CYP2B6 activ-
ity. CYP2B6 induction occurs despite the profound inhibition
of CYP3A4 activity.
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